PMID- 23186148
OWN - NLM
STAT- MEDLINE
DCOM- 20130625
LR  - 20231106
IS  - 1477-7819 (Electronic)
IS  - 1477-7819 (Linking)
VI  - 10
DP  - 2012 Nov 27
TI  - Pulmonary influences on early post-operative recovery in patients after 
      cytoreductive surgery and hyperthermic intraperitoneal chemotherapy treatment: a 
      retrospective study.
PG  - 258
LID - 10.1186/1477-7819-10-258 [doi]
AB  - BACKGROUND: The combination of cytoreductive surgery (CRS) and hyperthermic 
      intraperitoneal chemotherapy (HIPEC) is a curative treatment option for 
      peritoneal carcinomatosis (PC). There have been few studies on the pulmonary 
      adverse events (AEs) affecting patient recovery after this treatment, thus this 
      study investigated these factors. METHODS: Between January 2005 and December 
      2006, clinical data on all pulmonary AEs and the recovery progress were reviewed 
      for 76 patients with after CRS and HIPEC. Patients with pulmonary interventions 
      (thoracocenthesis and chest tubes) were compared with the non-intervention 
      patients. Two senior radiologists, blinded to the post-operative clinical course, 
      separately graded the occurrence of pulmonary AEs. RESULTS: Of the 76 patients, 6 
      had needed thoracocentesis and another 6 needed chest tubes. There were no 
      differences in post-operative recovery between the intervention and 
      non-intervention groups. The total number of days on mechanical ventilation, the 
      length of stay in the intensive care unit, total length of hospital stay, tumor 
      burden, and an American Society of Anesthesiologists (ASA) grade of greater than 
      2 were correlated with the occurrence of atelectasis and pleural effusion. 
      Extensive atelectasis (grade 3 or higher) was seen in six patients, major pleural 
      effusion (grade 3) in seven patients, and signs of heart failure (grade 1-2) in 
      nine patients. CONCLUSIONS: Clinical and radiological post-operative pulmonary 
      AEs are common after CRS and HIPEC. However, most of the pulmonary AEs did not 
      affect post-operative recovery.
FAU - Arakelian, Erebouni
AU  - Arakelian E
AD  - Department of Surgical Sciences, Section of Surgery, Uppsala University, Uppsala, 
      Sweden. erebouni.arakelian@surgsci.uu.se
FAU - Torkzad, Michael R
AU  - Torkzad MR
FAU - Bergman, Antonina
AU  - Bergman A
FAU - Rubertsson, Sten
AU  - Rubertsson S
FAU - Mahteme, Haile
AU  - Mahteme H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121127
PL  - England
TA  - World J Surg Oncol
JT  - World journal of surgical oncology
JID - 101170544
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/administration & dosage
MH  - Carcinoma/complications/pathology/*therapy
MH  - Chemotherapy, Cancer, Regional Perfusion/*adverse effects
MH  - Electrocoagulation/*adverse effects
MH  - Female
MH  - Humans
MH  - Hyperthermia, Induced/*adverse effects
MH  - Infusions, Parenteral
MH  - Lung Diseases/diagnosis/*etiology/therapy
MH  - Male
MH  - Middle Aged
MH  - Peritoneal Neoplasms/complications/pathology/*therapy
MH  - Recovery of Function
MH  - Retrospective Studies
MH  - Time Factors
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC3538602
EDAT- 2012/11/29 06:00
MHDA- 2013/06/26 06:00
PMCR- 2012/11/27
CRDT- 2012/11/29 06:00
PHST- 2012/07/17 00:00 [received]
PHST- 2012/10/31 00:00 [accepted]
PHST- 2012/11/29 06:00 [entrez]
PHST- 2012/11/29 06:00 [pubmed]
PHST- 2013/06/26 06:00 [medline]
PHST- 2012/11/27 00:00 [pmc-release]
AID - 1477-7819-10-258 [pii]
AID - 10.1186/1477-7819-10-258 [doi]
PST - epublish
SO  - World J Surg Oncol. 2012 Nov 27;10:258. doi: 10.1186/1477-7819-10-258.